I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.

Slides:



Advertisements
Similar presentations
12-1 Chapter 12 Advanced EHR Functionality © 2012 The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill.
Advertisements

Areas of Research Specific issues. Clinical Trials Phase I First use in humans of an experimental drug or treatment In a small group of healthy volunteers.
DSHS Texas Newborn Screening Program Processes Susan Tanksley, PhD David Martinez April 10, 2008.
Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
HIV Counselling and Testing
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.
Successful Solutions Professional Development LLC Chapter 3 Medication Management.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
Newborn Screening & Medical Foods Policy Overview Fatty Oxidation Disorders/Organic Acidemia Association Annual Conference July 26, 2014 Melanie Lockhart.
Ad Hoc Committee Update: Impact of NCAA Sickle Cell Trait Mandate Alexis Thompson January 16, 2014.
AMCHP 2005 Conference Newborn Screening in Maryland The Maryland Program Informed Consent Informational Materials Linkage to Services Challenges of Working.
Newborn Screening for Critical Congenital Heart Disease
Outline Definition of isolation Principles of Isolation Isolation Policy Policy implementation Personnel Roles & Responsibilities Visitation.
Treuman Katz Center for Pediatric Bioethics Conference Newborn Screening: The Future Revolution Beth A. Tarini, MD, MS Assistant Professor Child.
Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.
Chapter 15 Newborn (Perinatal) Guidelines ( )
Melissa Ewerth Graduate Adapted Physical Education, WCU.
In Collaboration with NewSTEPs: Data collection efforts at the national level for newborn screening quality improvement Marci K Sontag, PhD NewSTEPs (Newborn.
Michigan Birth Defects Registry Overview and Status.
Laboratory Management - 1
Genetic Screening for Cystic Fibrosis A New Choice for You and Your pregnancy.
Pulse oximetry screening for congenital heart disease. Does it work? Is it worth it?
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Consent for Research Study RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic Examinations ACRIN
 There are about 900 tests available for discovering genetic abnormalities.  Reasons for such testing include: › Finding possible genetic diseases in.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
GENTLE MEDICINE ASSOCIATES BOYNTON BEACH,FL Learning Session 2 April 27-28, 2012.
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
IMPROVING QUALTY OF CARE FOR CHILDREN TROUGH HEALTH IT Tennessee Project for Children with Special Health Care Needs AHRQ Annual Meeting September 26,2007.
Multiple Choice Questions for discussion
Newborn screening (NBS) is a simple procedure to find out if your baby has a congenital metabolic disorder that may lead to mental retardation and even.
CHILD HEALTH PROFILE FOR CHILDREN WITH SPECIAL HEALTH CARE NEEDS AAP Annual Meeting Council on Clinical Information Technology-October 28,2007 Carmen B.
Treuman Katz Center for Pediatric Bioethics Conference Banking Biological Samples for Pediatric Research Jeffrey R. Botkin, M.D., M.P.H. Professor.
Screening Implementation: Referral and Follow-up What Do You Do When the Screening Test Is of Concern? Paul H. Lipkin, MD D-PIP Training Workshop June.
Autism Screening C Eve J Kimball, MD All About Children Pediatric Partners, PC Preventive Services Improvement Project Learning Session 2 November 11-12,
Pediatric and Adolescent Health Partners February 12, 2011.
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
Ethical and Regulatory Considerations in Research using Residual Specimens Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics and Medical Ethics Associate.
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
Sustainability & Spread: Continue, Change! Marian Earls, MD Amy Pirretti, MS.
Evidence Review Group: Past to Present James M. Perrin, MD Professor of Pediatrics, Harvard Medical School MGH Center for Child and Adolescent Health Policy.
Module II: Feeding and HIV Testing for Exposed Infants This module, we will discuss: Unit 1: Infant Feeding Guidelines Unit 2: HIV Testing and Treatment.
We have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this.
1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?
Recommendation to ACHDNC for Newborn Screening for X-linked Adrenoleukodystrophy Fred Lorey, Ph.D. Don Bailey, Ph.D. Liaisons to the Condition Review Workgroup.
What does the Future Have in Store? The Roadmap for Phase 2 of C4K Ruth S. Gubernick, MPH Quality Improvement Advisor Florida Pediatric Medical Home Demonstration.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
We have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this.
Pompe Disease Evidence Evaluation Michael Watson, PhD, on behalf of Piero Rinaldo, MD, PhD, and the Decision-Making Workgroup October 1, 2008.
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.
Analysis of Genetic Disease Testing The Importance of Newborn Screening Ranimol N. Fromer Public Health Policy Analyst Michigan Department Health Department.
Pediatric ACOs The Characteristics of Pediatric Populations and Their Impact on ACOs.
Practice Key Driver Diagram. Chapter Quality Network ADHD Project Jen Powell, MPH, MBA Donna Williams The Parent Perspective.
University of Michigan Health System Children with Special Health Care Needs: Looking Back; Looking Forward Gary L. Freed, MD, MPH Director, Division of.
Established standards of care given with respect and consideration, regardless of race, age, or payment source. Information about your illness, possible.
Newborn Hearing Screening. R EPUBLIC A CT N O AN ACT ESTABLISHING A UNIVERSAL NEWBORN HEARING SCREENING PROGRAM FOR THE PREVENTION, EARLY DIAGNOSIS.
New policy starts 5th April 2016 IMPORTANT CHANGE TO BLOOD TRANSFUSION SAMPLE REQUIREMENTS Confirmation of a blood group from two samples taken on separate.
NEWBORN SCREENING SAVE YOUR BABY from MENTAL RETARDATION ZHALLENE MICHELLE E. SANCHEZ.
Retention period(s) of samples/data Many jurisdictions, as well as hospitals and institutions, mandate retention periods for medical or research-related.
Faculty Disclosure I do not have a significant financial relationship with the manufacturers of commercial products and/or providers of commercial services.
About Newborn Screening  Newborn Screening Facts - A brief introduction to the most important information on newborn screening.
Newborn Screening: Achieving Timeliness
WHY GENETIC COUNSELING IS IMPORTANT
The Early Hearing Detection & Intervention Program Overview
Newborn screening Dr Jim Bonham Clinical Director
Newborn screening is a type of population screening to detect rare and serious conditions that can be easily and hastily treated before serious symptoms.
Presentation transcript:

I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME activity. I do not intend to discuss an unapproved/investigative use of a commercial product/device in their presentation. Newborn Screening Top 10 Challenges Celia Kaye, MD, PhD, FAAP Robert A. Saul, MD, FAAP Newborn Screen Positive Infant ACTion Project Learning Session May 21-22, 2010

#1: Consent  Since newborn screening began in the 1960s, parent advocacy groups have played a pivotal role in its expansion. (Parents)  State health departments, already sensitive to patient privacy issues, have been quick to point out that blood spots are kept under lock and key. (Parents)  Informed consent is not required for newborn screening itself.

#2: Establishment of DNA Banks  “…activist groups around the country are frightening expectant parents by waving the red flag about privacy issues…” (Parents)  Why are leftover bloodspots stored? For quality control testing, development of new tests, and research under special circumstances (public health).  Many states store dried blood spots for only a short time. In some states that store spots longer, parents can choose not store their child’s sample.

#3: Research v. Screening  All states except a few permit parents to opt out of newborn screening.  Most states have strict IRB requirements and privacy policies for use of dried blood spots for research purposes. Some states are instituting specific consent for research use of dried blood spots.

#4: False Positive Results  False positive results are common in newborn screening and may be related to time of year, specimen testing procedure, geographic location (environment).  Parents should be informed that a positive screening result does not confirm a diagnosis, but medical care may be needed until the diagnosis is confirmed or ruled out.

#5: False Negatives  Missed (late diagnosed) cases are rare in newborn screening but may still occur.  One cause of missed cases is failure to screen; the pediatrician has an important role in making sure this doesn’t happen unless the parents opt out.  True false negatives will occur occasionally because of biologic variability.

#6: Second Screens  Most states require a single screen, but several states require a second screen at about two weeks of life.  Second screens may pick up disorders that were not detected on the first screen.  In states where the second screen is mandated, it is the pediatrician’s responsibility to check that this was done.

#7: New Tests on the Panel  There is a process (Secretary’s Advisory Committee on Hereditary Disorders in Newborns and Children) to add new tests to the recommended panel.  Several states require additional tests that are not yet included in the recommendations.  Tests to watch for: Krabbe disease, cyanotic congenital heart disease, lysosomal storage disease panel, Fragile-X, Hb H disease.

#8: When Your State Has a Pilot  Screening programs in individual states have elected to pilot certain newborn screening tests.  Special challenges: false positive and false negative rates not worked out, exact significance of “abnormal” results may not be clear, availability and utility of treatment may not be known, community education may be lacking.  State Newborn Screening Advisory Committee should provide guidance to pediatricians; pediatricians should seek involvement in such committees.

#9: What About Babies Adopted from Outside the U.S.?  Most newborn screening labs will accept samples after the newborn period (some up to 1 yr) if notified of age so that appropriate norms may be applied (if available) or results qualified.  While screening is possible, most newborn screening labs lack the properly developed infant norms, so infants should be evaluated for growth and development, and specific diagnostic tests should be considered if clinically indicated.

#10: The Promise Not Kept  Newborn screening has prevented morbidity and mortality for thousands of children.  Failure to ensure that screening occurred results in liability for hospitals and pediatricians.  Pediatricians should be aware of all of the newborn screening requirements in their state (conditions screened, number of screens required) and should document the results of all screens – no news is not considered good news!